(Q30583310)

20 August 2017

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States (English)

1 reference

20 August 2017

1 reference

Marko Kavcic

1

1 reference

20 August 2017

Brian T Fisher

2

1 reference

20 August 2017

Alix E Seif

3

1 reference

20 August 2017

Yimei Li

4

1 reference

20 August 2017

Yuan-Shung Huang

5

1 reference

20 August 2017

Dana Walker

6

1 reference

20 August 2017

Richard Aplenc

7

1 reference

20 August 2017

language of work or name

English

0 references

publication date

24 December 2012

1 reference

The Journal of Pediatrics

20 August 2017

1 reference

20 August 2017

162

1 reference

20 August 2017

6

1 reference

20 August 2017

1252-8, 1258.e1

1 reference

Does rituximab increase the incidence of infectious complications? A narrative review

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Rituximab as maintenance therapy for patients with follicular lymphoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Immune surveillance: a balance between protumor and antitumor immunity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Infectious complications associated with the use of rituximab for ABO-incompatible and positive cross-match renal transplant recipients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Safety of rituximab maintenance therapy in follicular lymphomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Measuring diagnoses: ICD code accuracy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3909336

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

26 November 2018

1 reference

12 December 2020

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma

1 reference

12 December 2020

Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases

1 reference

12 December 2020

Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis

1 reference

12 December 2020

Rituximab therapy for childhood-onset systemic lupus erythematosus

1 reference

12 December 2020

10.1016/J.JPEDS.2012.11.038

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

23269206

1 reference